University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
University of Muenster, Department of Neurosurgery, Muenster, Germany.
J Biomed Opt. 2023 May;28(5):050901. doi: 10.1117/1.JBO.28.5.050901. Epub 2023 May 13.
This third biennial intraoperative molecular imaging (IMI) conference shows how optical contrast agents have been applied to develop clinically significant endpoints that improve precision cancer surgery.
National and international experts on IMI presented ongoing clinical trials in cancer surgery and preclinical work. Previously known dyes (with broader applications), new dyes, novel nonfluorescence-based imaging techniques, pediatric dyes, and normal tissue dyes were discussed.
Principal investigators presenting at the Perelman School of Medicine Abramson Cancer Center's third clinical trials update on IMI were selected to discuss their clinical trials and endpoints.
Dyes that are FDA-approved or currently under clinical investigation in phase 1, 2, and 3 trials were discussed. Sections on how to move benchwork research to the bedside were also included. There was also a dedicated section for pediatric dyes and nonfluorescence-based dyes that have been newly developed.
IMI is a valuable adjunct in precision cancer surgery and has broad applications in multiple subspecialties. It has been reliably used to alter the surgical course of patients and in clinical decision making. There remain gaps in the utilization of IMI in certain subspecialties and potential for developing newer and improved dyes and imaging techniques.
第三届两年一度的术中分子成像（IMI）会议展示了光学对比剂如何被应用于开发具有临床意义的终点，以改善精准癌症手术。
IMI 的国内外专家介绍了癌症手术中的正在进行的临床试验和临床前工作。讨论了先前已知的染料（具有更广泛的应用）、新染料、新颖的非荧光成像技术、儿科染料和正常组织染料。
选择在佩雷尔曼医学院艾布拉姆森癌症中心进行的第三届 IMI 临床试验更新中进行演讲的主要研究者，以讨论他们的临床试验和终点。
讨论了已获得 FDA 批准或目前正在进行 1 期、2 期和 3 期临床试验的染料。还包括如何将基础研究转移到床边的部分。还专门为新开发的儿科染料和非荧光染料设立了一个部分。
IMI 是精准癌症手术的有价值的辅助手段，在多个亚专科中具有广泛的应用。它已被可靠地用于改变患者的手术过程和临床决策。在某些亚专科中，IMI 的应用仍存在差距，并且有潜力开发出更新、更好的染料和成像技术。
